Get the app
NSE › Healthcare

Hikal Limited (HIKAL)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹215.64-0.38%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
₹403 cr
Revenue YoY
+8.5%
Net profit
₹-7 cr
Net margin
-1.8%

Key statistics

Market cap
₹2,634 cr
Forward P/E
16.8
P/B
2.33
Book value
₹97.40
EPS (TTM)
₹-2.76
52-week high
₹260.32
52-week low
₹146.01
50-day MA
₹219.94
200-day MA
₹203.39
Beta
0.57

Analyst view

with an average price target of ₹300.00.

Shareholding

Promoters
68.85%
Institutions
6.59%

Largest named holders

HolderStake
Tata Mutual Fund - Tata Small Cap Fund2.68%
ICICI Prudential Healthcare Fund2.41%

Recent filings & reports

DocumentDate
Annual report FY20262026-08-31
Q1 FY27 earnings call
HIKAL LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: Rs 403 crores • Q1 FY27 EBITDA: Rs 37 crores at 9.2% margin • Q1 FY27 P
2026-08-12
Investor presentation · Q1 FY27
HIKAL LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Q1 FY27 Consolidated Revenue: ₹403 Crores (up 5.9% YoY from ₹380 Cr in Q1 FY26; dow
2026-08-06
Quarterly results · Q1 FY27
HIKAL LIMITED – Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue from Operations (Q1 FY27): Rs 4,028 million, down 22.4% YoY from Rs
2026-08-06
Q4 FY26 earnings call
HIKAL LIMITED - Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 519 crores | EBITDA: INR 105 crores | EBITDA Margin: 20.3% | PAT: I
2026-06-03
Investor presentation · Q4 FY26
HIKAL LIMITED – FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: Rs. 1,713 crores (down 8% from Rs. 1,860 crores in FY25) • FY26 EBITDA: Rs. 2
2026-05-27
Quarterly results · Q4 FY26
HIKAL LIMITED – DOCUMENT SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year (FY 2025-26) Revenue: ₹17,126 million (down 7.9% from ₹18,598 mil
2026-05-27
Quarterly results2026-04-13

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹0.40 / share
ex-date Sep 4, 2026
2026-09-04
Dividend₹0.20 / share
ex-date Feb 17, 2026
2026-02-17

Deals & corporate news

AnnouncementDate
New cGMP facility in Panoli begins commercial production
Hikal Limited announced that its new cGMP-compliant manufacturing facility at Panoli, Gujarat has begun commercial production of personal care products. This marks the company's formal entry
2026-09-22

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Hikal Limited — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.